Hyung-Jin Lee

Dr. Hyung-Jin Lee

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in Clinical Anatomy
Verified
Journal Article
Closed access
PDF file
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
SWSeong‐Yoon Won
Seong‐Yoon Won
JOJehoon O
Jehoon O
KHKyung-Seok Hu
Kyung-Seok Hu
SMSeo‐Young Mun
Seo‐Young Mun
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim

10 December 2022 in Toxins
Verified
Journal Article
Open access
PDF file
KYKyu-ho Yi
Kyu-ho Yi
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
KLKang-Woo Lee
Kang-Woo Lee
HHHye-Won Hu
Hye-Won Hu
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim
The platysma muscle is a thin superficial muscle that covers the entire neck and lower part of the face. The platysma muscle is the primary target muscle for botulinum neurotoxin injection therapy aimed at treating platysmal band and lower facial lifting. In the procedure of botulinum neurotoxin injection therapy, a lack of knowledge of the anatomy of the platysma muscle and the properties of botulinum neurotoxin can lead to side effects such as dysphagia, dysphonia, and weakness of the neck muscles. Anatomically safe injection sites have been proposed for the platysma muscle, and the appropriate injection technique has been reviewed. We proposed optimal injection sites based on the external anatomical features of the mandible. The aim of these proposal was to standardize the procedure for the effective use of botulinum neurotoxin injections by minimizing the dose unit and injection points and thereby preventing adverse events.

20 May 2014 in Surgical and Radiologic Anatomy
Verified
Journal Article
Closed access
PDF file
JLJae-Gi Lee
Jae-Gi Lee
HYHun-Mu Yang
Hun-Mu Yang
KHKyung-Seok Hu
Kyung-Seok Hu
YLYoung-Il Lee
Young-Il Lee
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim

30 December 2016 in Toxins
Verified
Journal Article
Open access
PDF file
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
IKIn-Won Kang
In-Won Kang
KSKyle K. Seo
Kyle K. Seo
YCYou-Jin Choi
You-Jin Choi
SKSeong Taek Kim
Seong Taek Kim
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim
The aim of this study was to determine the detailed anatomical structures of the superficial part of the masseter and to elucidate the boundaries and locations of the deep tendon structure within the superficial part of the masseter. Forty-four hemifaces from Korean and Thai embalmed cadavers were used in this study. The deep tendon structure was located deep in the lower third of the superficial part of the masseter. It was observed in all specimens and was designated as a deep inferior tendon (DIT). The relationship between the masseter and DIT could be classified into three types according to the coverage pattern: Type A, in which areas IV and V were covered by the DIT (27%, 12/44); Type B, in which areas V and VI were covered by the DIT (23%, 10/44); and Type C, in which areas IV, V, and VI were covered by the DIT (50%, 22/44). The superficial part of the masseter consists of not only the muscle belly but also the deep tendon structure. Based on the results obtained in this morphological study, we recommend performing layer-by-layer retrograde injections into the superficial and deep muscle bellies of the masseter.

25 March 2019 in Clinical Anatomy
Verified
Journal Article
Closed access
PDF file
Kyu-Lim LeeKyu-Lim Lee
Kyu-Lim Lee
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
KYKwan‐Hyun Youn
Kwan‐Hyun Youn
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim

4 January 2021 in Toxins
Verified
Journal Article
Open access
PDF file
Ji-Hyun LeeJi-Hyun Lee
Ji-Hyun Lee
SJSu-Jin Jung
Su-Jin Jung
SKSeong Taek Kim
Seong Taek Kim
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim
There are still concerns about masseteric bulging due to a lack of knowledge about the internal architecture of the masseter muscle. Further investigations are therefore required of the most-effective botulinum neurotoxin (BoNT) injection points and strategies for managing masseteric bulging. The purpose of this study was to identify safer and more effective botulinum neurotoxin injection points and strategies by using ultrasonography to determine the structural patterns of the deep inferior tendon. We also measured the precise depths and locations of the deep inferior tendon of the masseter muscle. Thirty-two healthy volunteers participated in this study, and ultrasonography was used to scan the masseter muscle both longitudinally and transversely. Three structural patterns of the deep inferior tendon were identified: in type A, the deep inferior tendon covered the anterior two-thirds of the masseter muscle (21.8%); in type B, the deep inferior tendon covered the posterior two-thirds of the masseter muscle (9.4%); and in type C, the deep inferior tendon covered most of the inferior part of the masseter muscle (68.8%). Depending on the ultrasonography scanning site, the depth from the skin surface to the mandible in the masseteric region ranged from 15 to 25 mm. The deep inferior tendon was typically located 2 to 5 mm deep from the mandible. Ultrasonography can be used to observe the internal structure of the masseter muscle including the deep inferior tendon in individual patients. This will help to reduce the side effects of masseteric bulging when applying retrograde or dual-plane injection methods depending on the structural pattern of the deep inferior tendon.